Surge in kidney ailments increases NHIF payment for renal dialysis

KENYA- Cost for covering renal dialysis has more than tripled over the last four years, as NHIF paid a whooping Ksh. 3.8 billion to cover dialysis expenses, indicating the growth in kidney disease burden among Kenyan citizens. The national social health insurer remitted 3.844 billion shillings 295,563 claims for patients who underwent renal dialysis procedures between June 2017 and June 2021 as soaring cases of chronic kidney diseases continue to burden the fund. This represented a 208 percent increase from the Ksh. 1.247 billion the NHIF paid for hemodialysis in…

Read More

FDA approves Cara’s drug for severe itching in kidney disease patients

USA – The Food and Drug Administration has approved Cara Therapeutics’s drug to treat moderate-to-severe itching in patients with chronic kidney disease undergoing dialysis, making it the first therapy for the ailment in the United States. The company expects to commercially launch the injection, Korsuva, in the first quarter of 2022, Chief Executive Officer Derek Chalmers said in an interview. The drug is designed to be administered three times a week after each dialysis. It reduces the activity of the sensory nerve that relays itching from the skin to the…

Read More

Bayer’s Kerendia can now be used in USA as therapy for chronic kidney disease in type 2 diabetes patients

US – Bayer’s first-in-class nonsteroidal drug Kerendia is now available in the US for use following an approval as a therapy that can slow chronic kidney disease progression in patients with type 2 diabetes. The approval is based on data from the Phase III FIDELIO-DKD renal outcomes study, which showed Kerendia significantly reduced the combined primary endpoint of chronic kidney disease progression, kidney failure or kidney death versus placebo when added to standard of care. Kerendia also lowered the risk of a composite of time to first occurrence of cardiovascular…

Read More